|
gptkbp:instanceOf
|
opioid
anilidopiperidine
|
|
gptkbp:approvedBy
|
1996
|
|
gptkbp:ATCCode
|
N01AH06
|
|
gptkbp:brand
|
Ultiva
|
|
gptkbp:CASNumber
|
132875-61-7
|
|
gptkbp:contraindication
|
hypersensitivity to opioids
|
|
gptkbp:discoveredBy
|
gptkb:Glaxo_Wellcome
|
|
gptkbp:eliminationHalfLife
|
3-10 minutes
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C20H28N2O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
remifentanil
|
|
gptkbp:IUPACName
|
methyl 1-(2-methoxycarbonylethyl)-4-(phenylpropionyl)piperidine-4-carboxylate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
plasma esterases
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
70%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
94513
104741
DB00899
|
|
gptkbp:riskFactor
|
addiction
respiratory arrest
abuse potential
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
hypotension
respiratory depression
bradycardia
|
|
gptkbp:UNII
|
Q5D430JZL9
|
|
gptkbp:usedFor
|
pain management
anesthesia
|
|
gptkbp:bfsParent
|
gptkb:FZ201
|
|
gptkbp:bfsLayer
|
8
|